DOI: 10.12890/2023_003838

Severe hypertriglyceridemia after use of bempedoic acid

Authors

  • Valentin Bovy Department of Internal Medicine, AZ Sint-Elisabeth Zottegem, Belgium
  • Anne-Marie Bogaert Department of Nephrology, AZ Sint-Elisabeth Zottegem, Belgium

valentin.bovy@student.kuleuven.be

Keywords

bempedoic acid, hypertriglyceridemia, adverse events

Abstract

Bempedoic is a new drug for the management of hypercholesterolemia, approved since 2020 by the EMA for use in Europe. In this case report, we describe a 65-year-old woman with sudden worsening of hypertriglyceridemia after the introduction of bempedoic acid. Triglyceride levels normalized quickly on withdrawal of the drug. With this case report, we want to reveal a possible association between bempedoic acid and the paradoxical occurrence of hypertriglyceridemia. Furthermore, we want to emphasize the limited evidence regarding the use of bempedoic acid in patients with pre-existing hypertriglyceridemia.

View the entire article

Downloads

References

  1. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al.; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2020;41:111–188.
  2. Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al.; CLEAR Harmony Trial. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med 2019;380:1022–1032.
  3. Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc 2019;8:e011662.
  4. Banach M, Duell PB, Gotto AM, Laufs U, Leiter LA, Mancini GBJ, et al. Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia. JAMA Cardiol 2020;5:1124–1135.
  5. Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 2023; doi: 10.1056/NEJMoa2215024.
  6. Cicero AFG, Pontremoli R, Fogacci F, Viazzi F, Borghi C. Effect of bempedoic acid on serum uric acid and related outcomes: a systematic review and meta-analysis of the available phase 2 and phase 3 clinical studies. Drug Saf 2020;43:727–736.
  7. Ray KK, Bakris GL, Banach M, Catapano A, Duell PB, Mancini GBJ, et al. Effect of bempedoic acid on uric acid and gout in 3621 patients with hypercholesterolemia: pooled analyses from phase 3 trials. Eur Heart J 2020;41:ehaa946.3001.
  8. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method of estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–245.

Published

2023-04-13

Issue

Vol. 10 No. 5 (2023)

Categories

How to Cite

1.
Bovy V, Bogaert A-M. Severe hypertriglyceridemia after use of bempedoic acid. EJCRIM [Internet]. 2023 Apr. 13 [cited 2026 Nov. 3];10(5). Available from: https://ejcrim.com/index.php/ejcrim/article/view/3838